Furthermore, novel evidence was provided that ERK1/2 signaling is activated in SVAS iPSC-SMC and accounted for their hyper-proliferation, which suggested that inhibition of cellular proliferation by decreasing ERK1/2 signaling might be potential therapeutic strategies in SVAS patients [89]. Here, MAPK3 is linked to supravalvular aortic stenosis.